Convection-Enhanced Delivery of Topotecan Active in Glioblastoma
Chronic convection-enhanced delivery of topotecan was feasible and well tolerated in patients with recurrent glioblastoma.
Brain Cancer
Cancer-Related Mortality Tied to Residential Segregation
Residential racial and economic segregation across US counties is associated with higher cancer mortality, a study suggests.
Dendritic Cell Vaccine Improves Upon Standard Care for Glioblastoma
Adding an autologous tumor lysate-loaded dendritic cell vaccine to standard care improves survival in patients with glioblastoma, a phase 3 study suggests.
Pediatric Cancer Survivors Experience Premature Aging
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Most Phase 3 Trials of Newly Diagnosed Glioblastoma Show No Improvement in OS
Most recent phase 3 trials of patients with newly diagnosed glioblastoma have shown no significant improvement in overall survival with the experimental treatment.
Deaths on the Rise in Patients With Malignant Brain Tumors
Deaths among patients with primary malignant brain tumors are on the rise in the United States, data suggest.
Risk of COVID-19 and Poor Outcomes Not Increased Among Glioma Patients
Patients with glioma do not have an increased risk of SARS-CoV-2 infection or worse outcomes from COVID-19, a single-center study suggests.
Neuroophthalmological Late Effects Common in Pediatric/Adolescent Medulloblastoma
Children and adolescents with medulloblastoma frequently suffer from neuroophthalmological sequelae, a single-center study suggests.
Predicting Outcomes of Regorafenib in Patients With Recurrent Glioblastoma
Researchers say they have identified a molecular signature that can be used to predict outcomes of regorafenib treatment in patients with recurrent glioblastoma.
Novel Agent Plus Radiotherapy Shows Promise in MGMT-Unmethylated Glioblastoma
VAL-083 in combination with radiotherapy is safe and active in patients with newly diagnosed MGMT-unmethylated glioblastoma, a phase 2 trial suggests.
- Loading...
Loading...
Next post in SNO 2022
Loading... 
Loading...